Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment

Overview

Journal J Ophthalmol

Publisher Wiley

Specialty Ophthalmology

Date 2017 Aug 9

PMID 28785483

Citations 25

Authors

Yan Cao

Wensong Zhang

Jie Wu

Hong Zhang

Hongyan Zhou

Affiliations

Soon will be listed here.

Abstract

Peripheral ulcerative keratitis (PUK) is type of crescent-shaped inflammatory damage that occurs in the limbal region of the cornea. PUK is always combined with an epithelial defect and the destruction of the peripheral corneal stroma. PUK may have a connection to systemic conditions, such as long-standing rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Wegener granulomatosis (WG), relapsing polychondritis, classic polyarteritis nodosa and its variants, microscopic polyangiitis, and Churg-Strauss syndrome. However, the most common connection is with RA, which is also the focus of this review. The pathogenesis of PUK is still unclear. It is thought that circulating immune complexes and cytokines exert an important influence on the progression of this syndrome. Treatment is applied to inhibit certain aspects of PUK pathogenesis.

Citing Articles

Regenerative Therapy for Corneal Scarring Disorders.

Chandran C, Santra M, Rubin E, Geary M, Yam G Biomedicines. 2024; 12(3).

PMID: 38540264 PMC: 10967722. DOI: 10.3390/biomedicines12030649.

Unveiling Ocular Manifestations in Systemic Lupus Erythematosus.

Musa M, Chukwuyem E, Ojo O, Topah E, Spadea L, Salati C J Clin Med. 2024; 13(4).

PMID: 38398361 PMC: 10889738. DOI: 10.3390/jcm13041047.

Ocular manifestations of granulomatosis with polyangiitis: report from a tertiary eye care center.

Korkmaz I, Selver O, Egrilmez S, Yagci A, Keser G, Aksu K Int Ophthalmol. 2024; 44(1):16.

PMID: 38321188 DOI: 10.1007/s10792-024-02989-y.

Freeze-dried amniotic membrane graft with a spongy layer in bilateral peripheral ulcerative keratitis: a case report.

Bertret C, Leveziel L, Knoeri J, Georgeon C, Jamart C, Bouheraoua N BMC Ophthalmol. 2023; 23(1):387.

PMID: 37735358 PMC: 10515264. DOI: 10.1186/s12886-023-03129-3.

Connective tissue disorders and eye: A review and recent updates.

Asif M, Kalra N, Sharma N, Jain N, Sharma M, Sinha R Indian J Ophthalmol. 2023; 71(6):2385-2398.

PMID: 37322648 PMC: 10418020. DOI: 10.4103/ijo.IJO_286_22.

References

van Baarsen L, Lebre M, van der Coelen D, Aarrass S, Tang M, Ramwadhdoebe T . Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?. Arthritis Res Ther. 2014; 16(4):426. PMC: 4292832. DOI: 10.1186/s13075-014-0426-z. View

Emery P, Fleischmann R, Doyle M, Strusberg I, Durez P, Nash P . Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function.... Arthritis Care Res (Hoboken). 2013; 65(11):1732-42. DOI: 10.1002/acr.22072. View

Gottschalk T, Tsantikos E, Hibbs M . Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus. Front Immunol. 2015; 6:550. PMC: 4623412. DOI: 10.3389/fimmu.2015.00550. View

Keystone E, Genovese M, Hall S, Miranda P, Bae S, Palmer W . Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol. 2013; 40(7):1097-103. DOI: 10.3899/jrheum.120584. View

Buch M, Smolen J, Betteridge N, Breedveld F, Burmester G, Dorner T . Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011; 70(6):909-20. PMC: 3086093. DOI: 10.1136/ard.2010.144998. View

Shoughy S, Tabbara K . Ocular findings in systemic lupus erythematosus. Saudi J Ophthalmol. 2016; 30(2):117-21. PMC: 4908056. DOI: 10.1016/j.sjopt.2016.02.001. View

Pahor D, Gracner B, Gracner T, Pahor A . [Ocular symptoms as the initial signs of Wegener's granulomatosis]. Klin Monbl Augenheilkd. 2009; 226(5):409-13. DOI: 10.1055/s-0028-1109255. View

Messmer E, Foster C . Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management. Cornea. 1995; 14(4):408-17. DOI: 10.1097/00003226-199507000-00010. View

Miossec P, Korn T, Kuchroo V . Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009; 361(9):888-98. DOI: 10.1056/NEJMra0707449. View

10.

Odorcic S, Keystone E, Ma J . Infliximab for the treatment of refractory progressive sterile peripheral ulcerative keratitis associated with late corneal perforation: 3-year follow-up. Cornea. 2008; 28(1):89-92. DOI: 10.1097/ICO.0b013e318181a84f. View

11.

Burska A, Hunt L, Boissinot M, Strollo R, Ryan B, Vital E . Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators Inflamm. 2014; 2014:492873. PMC: 3981057. DOI: 10.1155/2014/492873. View

12.

Rosman Z, Shoenfeld Y, Zandman-Goddard G . Biologic therapy for autoimmune diseases: an update. BMC Med. 2013; 11:88. PMC: 3616818. DOI: 10.1186/1741-7015-11-88. View

13.

Kaplan C, Valdez J, Chandrasekaran R, Eibel H, Mikecz K, Glant T . Th1 and Th2 cytokines regulate proteoglycan-specific autoantibody isotypes and arthritis. Arthritis Res. 2002; 4(1):54-8. PMC: 64852. DOI: 10.1186/ar383. View

14.

Silpa-Archa S, Lee J, Foster C . Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol. 2015; 100(1):135-41. DOI: 10.1136/bjophthalmol-2015-306629. View

15.

Truchetet M, Mossalayi M, Boniface K . IL-17 in the rheumatologist's line of sight. Biomed Res Int. 2013; 2013:295132. PMC: 3741932. DOI: 10.1155/2013/295132. View

16.

Yoshida T, Mei H, Dorner T, Hiepe F, Radbruch A, Fillatreau S . Memory B and memory plasma cells. Immunol Rev. 2010; 237(1):117-39. DOI: 10.1111/j.1600-065X.2010.00938.x. View

17.

Alunno A, Manetti M, Caterbi S, Ibba-Manneschi L, Bistoni O, Bartoloni E . Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications. Mediators Inflamm. 2015; 2015:751793. PMC: 4397010. DOI: 10.1155/2015/751793. View

18.

Huerva V, Ascaso F, Grzybowski A . Infliximab for peripheral ulcerative keratitis treatment. Medicine (Baltimore). 2014; 93(26):e176. PMC: 4616390. DOI: 10.1097/MD.0000000000000176. View

19.

Subbarayal B, Chauhan S, Di Zazzo A, Dana R . IL-17 Augments B Cell Activation in Ocular Surface Autoimmunity. J Immunol. 2016; 197(9):3464-3470. PMC: 5101134. DOI: 10.4049/jimmunol.1502641. View

20.

Gou S, Yuan J, Chen M, Yu F, Zhao M . Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2012; 83(1):129-37. DOI: 10.1038/ki.2012.313. View